At ASH 2021, CancerNetwork® spoke with Ruben Mesa, MD, of UT Health San Antonio MD Anderson Cancer Center, about phase 3 trial results regarding myelofibrosis that he is most excited about.
I’m the most interested to see the MANIFEST-2 study [NCT04603495]. This is a clinical trial of pelabresib [CPI-0610] with ruxolitinib [Jakafi] in JAK2-inhibitor naïve patients. The earlier studies showed deep benefits for spleen and symptoms with potential improvements both in anemia and fibrosis. If approved, it really would be the first time we’ve changed the paradigm of upfront JAK2 inhibitor therapy to potentially being a combination. There’s some other important ones on its heels, [such as] the combination with navitoclax, a [BCL-XL] inhibitor, along with ruxolitinib; an the MDM2 inhibitor along with ruxolitinib; a PI3K inhibitor along with ruxolitinib. There’s a real theme there in terms of multiple different mechanisms of action, but the one furthest along is the one with pelabresib and the one we’re eager to see first.